A detailed history of Van Eck Associates Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 251,650 shares of ABBV stock, worth $45.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
251,650
Previous 226,402 11.15%
Holding current value
$45.3 Million
Previous $38.8 Million 21.75%
% of portfolio
0.06%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$163.84 - $199.33 $4.14 Million - $5.03 Million
25,248 Added 11.15%
251,650 $47.3 Million
Q2 2024

Jul 31, 2024

BUY
$154.79 - $180.76 $1.41 Million - $1.65 Million
9,105 Added 4.19%
226,402 $38.8 Million
Q1 2024

Apr 30, 2024

BUY
$159.82 - $182.1 $7.88 Million - $8.97 Million
49,284 Added 29.33%
217,297 $39.6 Million
Q4 2023

Feb 05, 2024

SELL
$137.6 - $154.97 $122,876 - $138,388
-893 Reduced 0.53%
168,013 $26 Million
Q3 2023

Nov 08, 2023

BUY
$133.59 - $154.65 $1.34 Million - $1.55 Million
10,015 Added 6.3%
168,906 $25.2 Million
Q2 2023

Aug 03, 2023

BUY
$132.51 - $164.9 $203,667 - $253,451
1,537 Added 0.98%
158,891 $21.4 Million
Q1 2023

May 03, 2023

SELL
$144.61 - $166.54 $9.4 Million - $10.8 Million
-65,003 Reduced 29.23%
157,354 $25.1 Million
Q4 2022

Feb 08, 2023

SELL
$138.31 - $165.87 $10.2 Million - $12.2 Million
-73,685 Reduced 24.89%
222,357 $35.9 Million
Q3 2022

Oct 27, 2022

BUY
$134.21 - $153.93 $2.7 Million - $3.1 Million
20,135 Added 7.3%
296,042 $39.7 Million
Q2 2022

Aug 03, 2022

BUY
$137.62 - $174.96 $6.29 Million - $7.99 Million
45,678 Added 19.84%
275,907 $42.3 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $1.65 Million - $2.05 Million
12,513 Added 5.75%
230,229 $37.3 Million
Q4 2021

Jan 26, 2022

SELL
$107.43 - $135.93 $1.61 Million - $2.04 Million
-15,023 Reduced 6.45%
217,716 $29.5 Million
Q3 2021

Nov 03, 2021

BUY
$106.4 - $120.78 $6.29 Million - $7.14 Million
59,097 Added 34.03%
232,739 $25.1 Million
Q2 2021

Aug 10, 2021

SELL
$105.21 - $117.21 $22.1 Million - $24.6 Million
-210,029 Reduced 54.74%
173,642 $19.6 Million
Q1 2021

May 13, 2021

BUY
$102.3 - $112.62 $811,239 - $893,076
7,930 Added 2.11%
383,671 $41.5 Million
Q4 2020

Feb 09, 2021

BUY
$80.49 - $108.67 $15 Million - $20.2 Million
186,084 Added 98.12%
375,741 $40.3 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $506,869 - $594,897
-5,900 Reduced 3.02%
189,657 $16.6 Million
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $1.09 Million - $1.45 Million
14,813 Added 8.2%
195,557 $19.2 Million
Q1 2020

May 12, 2020

SELL
$64.5 - $97.79 $1.17 Million - $1.77 Million
-18,110 Reduced 9.11%
180,744 $13.8 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $2.03 Million - $2.54 Million
28,163 Added 16.5%
198,854 $17.6 Million
Q3 2019

Nov 08, 2019

SELL
$62.98 - $75.72 $218,288 - $262,445
-3,466 Reduced 1.99%
170,691 $12.9 Million
Q2 2019

Aug 07, 2019

SELL
$65.7 - $83.98 $269,698 - $344,737
-4,105 Reduced 2.3%
174,157 $12.7 Million
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $292,206 - $343,912
-3,788 Reduced 2.08%
178,262 $14.4 Million
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $19,851 - $24,482
-255 Reduced 0.14%
182,050 $16.8 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $694,031 - $771,545
7,806 Added 4.47%
182,305 $17.2 Million
Q2 2018

Aug 13, 2018

BUY
$89.78 - $106.23 $5.87 Million - $6.94 Million
65,367 Added 59.9%
174,499 $16.2 Million
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $3.1 Million - $4.15 Million
-33,650 Reduced 23.57%
109,132 $10.3 Million
Q4 2017

Feb 12, 2018

SELL
$89.56 - $98.21 $3.25 Million - $3.56 Million
-36,237 Reduced 20.24%
142,782 $13.8 Million
Q3 2017

Nov 09, 2017

SELL
$69.85 - $89.22 $1.49 Million - $1.9 Million
-21,263 Reduced 10.62%
179,019 $15.9 Million
Q2 2017

Aug 11, 2017

BUY
N/A
200,282
200,282 $14.5 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.